Thereby, the question about the utility of HER2/ECD as a useful circulating biomarker to follow the trastuzumab therapy efficacy during the neoadjuvant treatment of invasive breast cancer with HER2 overexpression, while CA 15.3 cannot, remains to be addressed in future studies. This evidence concerns the gene ERBB2 and invasive breast carcinoma.